Targeting prostaglandin catabolism via topical nanotherapy rescues vision in ischemic optic neuropathy
These findings establish 15-PGDH–mediated prostaglandin catabolism as a therapeutic target in ischemic optic neuropathy and demonstrate a clinically translatable nanotherapeutic strategy for protecting the central nervous system from ischemic neurodegeneration.